SpliceBio, S.L.

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

In a biopharma ecosystem with reduced cash flow, even established companies must focus more on demonstrating their unique value proposition. Companies of all sizes are concentrating on how to “show in

While most biotechs struggle amid a prolonged funding winter, one group is doing just fine. We are not talking about artificial intelligence. Several start-ups working on nucleic acid-based therapies

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With Verve Again By Acqu